Get all premium features to the best stock analysis tool

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego.

The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended December 31, 2025. Relative strength in Information Technology and Industrials outweighed relative weakness in Consumer Discretionary and Communication Services. The Fund's largest sector change was in the Industrials sector, where we increased exposure. Industrials currently represent the Fund's largest overweight relative to the index.

Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.

Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.

Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript